BAGSVAERD, DENMARK-(Marketwire - September 6, 2010) - [HUG#1442788] Company Announcement no 49 2010: http:/hugin.info/2013/R/1442788/387001.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants (…)
[Read article]
[Source: Marketwire]
Marseilles, France, August 31, 2010 -Innate Pharma SA (the Company - Euronext Paris: FR0010331421 IPH) announces today its financial results for the first half of 2010. The key financial elements for the half-year results are as follows: ? A decrease in the operating loss (…)
[Read article]
[Source: BioSpace]
BAGSVÃ RD, DENMARK-(Marketwire - August 30, 2010) - [HUG#1441251] Company Announcement no 48 2010: http:/hugin.info/2013/R/1441251/385568.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants (…)
[Read article]
[Source: Marketwire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/37adf0/eli_lilly_co_p) has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)
[Read article]
[Source: Business Wire]
BAGSVaeRD, DENMARK-(Marketwire - August 30, 2010) - [HUG#1441251] Company Announcement no 48 2010: http:/hugin.info/2013/R/1441251/385568.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/db0b08/type_2_diabetes) has announced the addition of GlobalData 's new report "Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017" to their offering. Type 2 Diabetes - (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/883f56/novel_antibodies_a) has announced the addition of the "Novel Antibodies and Therapeutic Proteins - Technology Challenges and Future Prospects" report to their offering. Novel (…)
[Read article]
[Source: Business Wire]
Objective: This report examines current perspectives regarding likely mechanisms of beta-cell failure in type 2 diabetes and their clinical implications for protecting or sparing beta-cells early in the disease progression. In addition, it considers translation strategies to (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e9e8b4/educating_the_mark) has announced the addition of the "Educating the Market: Creating Value Through Support of Continuing Medical Education 2010" report to their offering. Educating (…)
[Read article]
[Source: Business Wire]
SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection. ZymoGenetics is investigating PEG-Interferon lambda in (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/81e154/raising_disease_st) has announced the addition of the "Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products" report to their offering. (…)
[Read article]
[Source: Business Wire]
BAGSVAERD, DENMARK-(Marketwire - August 23, 2010) - [HUG#1439544] Company Announcement no 47 2010: http:/hugin.info/2013/R/1439544/383928.pdf Media: Investors: Anne Margrethe Hauge Klaus Bülow Davidsen Tel: (+45) 4442 3450 Tel: (+45) 4442 3176 amhg@novonordisk.com (…)
[Read article]
[Source: Marketwire]
The cannabinoid receptor 1 antagonist, rimonabant, reduces food intake and body weight, but contradictory findings have been reported as to whether the weight-reducing effect is fully accounted for by the reduced food intake or if rimonabant also mediates a lipolytic effect. In (…)
[Read article]
[Source: NCBI PubMed]
Individuals with BRCA2 mutations are predisposed to breast cancers owing to genome instability. To determine the functions of BRCA2, the human protein was purified. It was found to bind selectively to single-stranded DNA (ssDNA), and to ssDNA in tailed duplexes and replication (…)
[Read article]
[Source: NCBI PubMed]
Summary Objective: Recombinant human growth hormone (rhGH) replacement therapy in children and adults currently requires daily subcutaneous injections for several years or lifelong. The current study examined safety, tolerability, pharmacokinetic and pharmacodynamic response (…)
[Read article]
[Source: NCBI PubMed]
Liraglutide is a novel once-daily human glucagon-like peptide (GLP)-1 analog in clinical use for the treatment of type 2 diabetes. To study metabolism and excretion of [(3)H]-liraglutide, a single subcutaneous dose of 0.75 mg/14.2 MBq was given to healthy males. The recovered (…)
[Read article]
[Source: NCBI PubMed]
Diabetes Self Manag. |-| Paulsen T. |-| Novo Nordisk, Inc.
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2061ac/effective_social_m) has announced the addition of the "Effective Social Media Marketing Strategies for Pharmaceutical Market" report to their offering. Effective Social Media (…)
[Read article]
[Source: Business Wire]
NovoPen(R), the first insulin pen, was introduced in 1985. This review article is an update of a review paper published in 2006 on 20 years' use of the NovoPen(R) family of insulin pens in the management of diabetes mellitus. The literature searches conducted in the earlier (…)
[Read article]
[Source: NCBI PubMed]
BAGSVAERD, DENMARK-(Marketwire - August 12, 2010) - As part of the execution of Novo Nordisk A /S' DKK 8.5 billion share repurchase programme for 2010, a share repurchase programme has been initiated in accordance with the provisions of the European Commission's regulation no (…)
[Read article]
[Source: Marketwire]
HAYWARD, Calif.-(BUSINESS WIRE)-Aradigm Corporation (OTCBB:ARDM) (the Company ) today announced financial results for the second quarter and six months ended June 30, 2010. The Company s net loss for the second quarter of 2010 was approximately $4.1 million, or $0.04 per (…)
[Read article]
[Source: Business Wire]
BACKGROUND: Little is known about international variation in mortality after severe trauma. This study examines variation in mortality, injury severity, and case management among countries from a recent prospective multinational trauma trial. METHODS: This trauma trial was a (…)
[Read article]
[Source: NCBI PubMed]
BAGSVAERD, DENMARK-(Marketwire - August 12, 2010) - Novo Nordisk A/S has today entered into an agreement to purchase 5,100,000 B shares (nominal DKK 1) from Novo A/S as part of the ongoing DKK 8.5 billion share repurchase programme for 2010. The transaction price is set to DKK (…)
[Read article]
[Source: BioSpace]
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved NovoSeven RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. (…)
[Read article]
[Source: Medical News Today]
PRNewswire - Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved NovoSeven RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, (…)
[Read article]
[Source: BioSpace]
WASHINGTON-(BUSINESS WIRE)-The Biotechnology Industry Organization (BIO) today announced initial companies selected through a competitive screening process to present at the inaugural BIO India International Partnering Conference. These firms are a snapshot representing the (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/045efe/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Brazil" report to their offering. These highly regarded world pharmaceutical market reports have (…)
[Read article]
[Source: Business Wire]
CORAL SPRINGS, FL-(Marketwire - August 09, 2010) - Highlighted Links Nyloxin Chronic Pain Relief Nutra Pharma Corporation Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (…)
[Read article]
[Source: BioSpace]
Abstract Although there are some interactions between the major pediatric diabetes programs in the United States, there has been no formal, independent structure for collaboration, the sharing of information, and the development of joint research projects that utilize common (…)
[Read article]
[Source: NCBI PubMed]
BAGSVAERD, DENMARK-(Marketwire - August 6, 2010) - [HUG#1436459] Company Announcement no 44 2010: http:/hugin.info/2013/R/1436459/381527.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (…)
[Read article]
[Source: Marketwire]
WALTHAM, Mass.-(BUSINESS WIRE)-Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, announced that the United States Department of Justice has closed its investigation of the proposed acquisition of (…)
[Read article]
[Source: Business Wire]
BAGSVAERD, DENMARK-(Marketwire - August 06, 2010) - [HUG#1436459] Company Announcement no 44 2010: http:/hugin.info/2013/R/1436459/381527.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants (…)
[Read article]
[Source: BioSpace]
BAGSVAERD, DENMARK-(Marketwire - August 05, 2010) - Novo Nordisk increased operating profit by 19% in the first half of 2010 Sales growth of 14% driven by modern insulins and Victoza(r) [HUG#1435910] Company Announcement no 43 2010: http:/hugin.info/2013/R/1435910/381105.pdf (…)
[Read article]
[Source: BioSpace]
BAGSVAERD, DENMARK-(Marketwire - August 4, 2010) - [HUG#1435715] Company Announcement no 42 2010: http:/hugin.info/2013/R/1435715/381012.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (…)
[Read article]
[Source: Marketwire]
ORLANDO, FL-(Marketwire - August 4, 2010) - Novo Nordisk (NYSE: NVO) presented results today demonstrating that once-daily Victoza (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American (…)
[Read article]
[Source: Marketwire]
Pharmaceutical company Novo Nordisk's decision to pull its Mixtard 30 insulin drug from the UK could add £9 million to the NHS drugs bill in England alone, says an editorial in the Drug and Therapeutics Bulletin (DTB) (a BMJ publication). The decision could also leave (…)
[Read article]
[Source: Medical News Today]
SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that Douglas E. Williams, Ph.D., Chief Executive Officer of ZymoGenetics, will present at the Canaccord Annual Growth Conference in Boston on Tuesday, August 10, 2010 at 8:30 a.m. Eastern Time. A live (…)
[Read article]
[Source: Business Wire]
BAGSVAERD, DENMARK-(Marketwire - August 04, 2010) - [HUG#1435715] Company Announcement no 42 2010: http:/hugin.info/2013/R/1435715/381012.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants (…)
[Read article]
[Source: BioSpace]
Medical News Today - Pharmaceutical company Novo Nordisk's decision to pull its Mixtard 30 insulin drug from the UK could add £9 million to the NHS drugs bill in England alone, says an editorial in the Drug and Therapeutics Bulletin (DTB) (a BMJ publication).
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/4f2248/russia_diabetes_ma) has announced the addition of the "Russia Diabetes Management Devices Market Assessment and Forecasts to 2015" report to their offering. Russia Diabetes (…)
[Read article]
[Source: Business Wire]
SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported substantially improved financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the company s net loss declined to $3.8 million, or $0.04 per share, a $23.2 million (…)
[Read article]
[Source: Business Wire]
BAGSVAERD, DENMARK-(Marketwire - August 2, 2010) - On 27 April 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. (…)
[Read article]
[Source: Marketwire]